You might be eligible to participate in the study.
Share your results and the study information with your doctor.
Aged 18 or older
Have a confirmed diagnosis of chronic primary ITP
Have tried at least two ITP therapies that have not worked or stopped working
You don't have to go it alone. For help in connecting to the study, contact us.
For your doctor: Description of the Meza ITP study
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia
clinicaltrials.gov listing: NCT06722235
This website is intended only for residents of the United Kingdom.
TAK-079-3002_Meza ITP_Patient Website_V1.0_26 AUGUST2025_UK